<DOC>
	<DOCNO>NCT00788736</DOCNO>
	<brief_summary>The main objective study develop validate clinical prediction rule major bleed patient oral anticoagulant therapy safely anticoagulated without bleed venous thromboembolism ( VTE ) recurrence least 3 month since diagnosis consider long-term oral anticoagulant therapy .</brief_summary>
	<brief_title>Predicting Bleeding Risk Anticoagulant Therapy Venous Thromboembolism</brief_title>
	<detailed_description>Oral anticoagulant therapy patient risk develop blood clotting problem use 400,000-600,000 Canadians annually . The use drug represent common cause patient adverse medical outcome due medical error . Furthermore , many patient adverse outcome use drug physician able predict patient likely bleed outcomes . Much effort go develop way predict patient risk clot almost work go way predict patient would high risk bleeding . This information require balance risk-benefits enable physician patient understand risk benefit take medication . Our study develop tool use predict bleed risk patient take oral anticoagulant therapy . It enable informed decision make physician patient result good control use drug . In addition , patient risk difficult accurately dose oral anticoagulant identify study .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>&gt; =18 year old provoke unprovoked venous thromboembolism objectively confirm venous thromboembolism treat oral anticoagulant ( vitamin K antagonist new oral anticoagulant ) least 3 month plan continue longterm take vitamin K antagonist ; INR target 2.03.0 take vitamin K antagonist ; must take last 3 consecutive week ( minimum ) major bleed take oral anticoagulant active bleeding study enrollment active cancer current time VTE diagnosis unable provide write informed consent refusal provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>venous thromboembolism</keyword>
	<keyword>long-term oral anticoagulant therapy</keyword>
	<keyword>warfarin</keyword>
	<keyword>bleeding risk</keyword>
	<keyword>clinical prediction rule</keyword>
	<keyword>predictor</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>vitamin k antagonist</keyword>
	<keyword>side effect</keyword>
</DOC>